Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

Kalra, Sanjay; Plata-Que, Teresa; Kumar, Dileep; Mumtaz, Malik; Søndergaard, Flemming L.; Kozlovski, Plamen; Bebakar, Wan Mohamad Wan

doi:10.1016/j.diabres.2010.03.004

Cited by 22 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The process of selecting the RCTs utilised in the final analyses from the 2700 citations, originally identified, is described in Figure 1. We found 87 studies (14–100) with a total of 135 arms that satisfied the inclusion/exclusion criteria. Most trials were multinational and sponsored by industry.…”

Section: Resultsmentioning

confidence: 99%

Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials

Giugliano

Maiorino

Bellastella

et al. 2011

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials

Giugliano

Maiorino

Bellastella

et al. 2011

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Asian evidence which proves the need for greater prandial insulin coverage,[14] and the advantages of specific insulin preparations should be taken into consideration. [15]…”

Section: Insulin For Type 2 Diabetes In Southeast Asiamentioning

confidence: 99%

Choice of insulin in type 2 diabetes: A Southeast Asian perspective

Kalra

Thai

Deerochanawong

et al. 2017

Indian J Endocr Metab

Self Cite

View full text Add to dashboard Cite

Southeast Asia faces a diabetes epidemic, which has created significant challenges for health care. The unique Asian diabetes phenotype, coupled with peculiar lifestyle, diet, and healthcare-seeking behavior, makes it imperative to develop clinical pathways and guidelines which address local needs and requirements. From an insulin-centric viewpoint, the preparations prescribed in such pathways should be effective, safe, well tolerated, nonintrusive, and suitable for the use in multiple clinical situations including initiation and intensification. This brief communication describes the utility of premixed or dual action insulin in such clinical pathways and guidelines.

show abstract

“…[47] A third study that examined once-daily BIAsp 30 versus insulin glargine in an Asian population also reported similar results in terms of a small but statistically significant difference in HbA 1c lowering (−0.36% difference between groups; p = 0.015), a nonsignificantly higher rate of minor and daytime hypoglycaemia with BIAsp 30, no difference in nocturnal hypoglycaemia, low rates of serious adverse events, low rates of major hypoglycaemic episodes and similar mean bodyweight increase in both groups. [59] In addition, Yang et al[67,68] explored BIAsp 30 three times daily as a starting insulin in Chinese patients with type 2 diabetes. In this population, three daily BIAsp 30 injections provided better PPG control after lunch and dinner, and greater HbA 1c reductions over 24 weeks than twice-daily BIAsp 30 (values reached 7.01% vs 6.68%; p < 0.01 for change from baseline).…”

Section: Safety and Efficacy Of Biasp 30mentioning

confidence: 99%

Ten Years of Experience with Biphasic Insulin Aspart 30

Liebl

Prusty

Valensi

et al. 2012

Drugs

View full text Add to dashboard Cite

Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that provides coverage of prandial and basal insulin in a single injection. As BIAsp 30 has been available internationally for 10 years, this review provides a comprehensive overview of the discovery of BIAsp 30, its pharmacokinetic and pharmacodynamic profile, safety and efficacy outcomes from the clinical trial programme, ‘real-life’ clinical insights provided by observational study data, and cost effectiveness and quality-of-life information. These studies have demonstrated that BIAsp 30 once or twice daily is an appropriate option for insulin initiation. BIAsp 30 also provides a switch option in patients on biphasic human insulin (BHI). Switching from BHI to BIAsp 30 is associated with improved postprandial glucose (PPG) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with BIAsp 30. Intensification of BIAsp 30 can be achieved by increasing the number of daily doses up to three times daily with meals. Therefore, BIAsp 30 provides an intensification option for individuals who are not achieving control with basal insulin and would prefer the simplicity of a single biphasic insulin instead of progressing to a basal-bolus approach. BIAsp 30 has a simple dose-titration algorithm, which enables patients to effectively self-titrate their insulin dose. Cost-effectiveness analyses have demonstrated that BIAsp 30 is cost effective or dominant compared with BHI 30 or insulin glargine in a number of healthcare settings. In conclusion, BIAsp 30 offers a simple and flexible option for insulin initiation and intensification that provides coverage of both fasting and prandial glucose.

show abstract

Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

Cited by 22 publications

References 27 publications

Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials

Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials

Choice of insulin in type 2 diabetes: A Southeast Asian perspective

Ten Years of Experience with Biphasic Insulin Aspart 30

Contact Info

Product

Resources

About